Cash, cash equivalents and marketable securities at December 31, 2007 were $86.1 million, compared with $57.2 million as of December 31, 2006.
"A combination of product innovation and sales force excellence enabled us to deliver an outstanding year in 2007, and we expect that momentum to continue in 2008," Davin said. "Bolstered by Affirm and Smartlipo, our recent product introductions at AAD and new innovations planned for the coming quarters, we believe we are well positioned to produce sustained, profitable growth. Our goal is to continue to grow faster than the aesthetic market in the year ahead."
Use of Non-GAAP Financial Measures
To supplement Cynosure's consolidated financial statements presented in
accordance with GAAP, this press release includes the following measures
defined as non-GAAP financial measures by the SEC: non-GAAP net income and
non-GAAP diluted earnings per share. The presentation of this financial
information is not intended to be considered in isolation or as a
substitute for the financial information prepared and presented in
accordance with GAAP. In addition, the non-GAAP financial measures included
in this press release may be different from, and therefore not comparable
to, similar measures used by other companies. Although certain non-GAAP
financial measures used in this release exclude the accounting treatment of
stock-based compensation, these non-GAAP measures should not be relied upon
independently, as they ignore the contribution to our operating results
that is generated by the incentive and compensation effects of the
underlying stock-based compensation programs. For more information on these
non-GAAP financial measures
|SOURCE Cynosure, Inc.|
Copyright©2008 PR Newswire.
All rights reserved